Table 4 Determinants for clinical worsening and overall survival

From: Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort

  Clinical worsening Overall survival
Univariable analysis Multivariable analysis   Univariable analysis Multivariable analysis
  No. out of 178 (%) nevents/npatients HR (95% CI) P value (Wald) HR (95% CI) P value (Wald) nevents/npatients HR (95% CI) P value (Wald) HR (95% CI) P value (Wald)
Gender     0.19      0.17   
Female 102 (57%) 23/102 1     14/102 1    
Male 76 (43%) 24/76 1.47 (0.83–2.61)     17/76 1.64 (0.81–3.32)    
Age at diagnosis     0.50      0.04   
<70 years 128 (72%) 32/128 1     18/128 1    
≥70 years 50 (28%) 15/50 1.24 (0.67–2.28)     13/50 2.13 (1.04–4.36)    
BMI     0.39      0.52   
<18.5 12 (7%) 5/12 1.63 (0.60–4.43)     4/12 2.34 (0.73–7.45)    
18.5–25 64 (39%) 17/64 1     10/64 1    
25–30 62 (38%) 12/62 0.76 (0.36–1.60)     9/62 1.05 (0.43–2.59)    
≥30 25 (15%) 8/25 1.43 (0.61–3.33)     4/25 1.16 (0.36–3.69)    
Smoking (n = 152 with informative data)     0.03      0.01   
Never 89 (59%) 17/89 1     10/89 1    
Current/former 63 (41%) 22/63 2.03 (1.07–3.82)     17/63 2.78 (1.27–6.08)    
ECOG at last follow-up     <0.0001   <0.0001    <0.0001   <0.0001
0–1 129 (73%) 22/129 1   1   9/129 1   1  
≥2 48 (27%) 25/48 3.61 (2.03–6.42)   3.25 (1.81–5.85)   22/48 7.49 (3.45–16.3)   5.83 (2.60–13.1)  
Type of cancer     0.09   0.33    0.45   
Solid tumor 150 (84%) 36/150 1   1   27/150 1    
Hematological malignancy 28 (16%) 11/28 1.80 (0.91–3.55)   1.42 (0.70–2.88)   4/28 0.67 (0.23–1.90)    
Onco-hematological status     0.13      0.007   0.15
Remission/ localized 70 (39%) 13/70 1     4/70 1   1  
Active/metastatic 108 (61%) 34/108 1.64 (0.86–3.11)     27/108 4.23 (1.48–12.1)   2.22 (0.75–6.58)  
Treatment in the past 3months     0.20      0.17   
No 58 (33%) 11/58 1     6/58 1    
Yes 117 (67%) 35/117 1.55 (0.79–3.06)     24/117 1.87 (0.77–4.59)    
Cytotoxic chemotherapy in the past 3months     0.008   0.09    0.03   0.23
No 112 (63%) 21/112 1   1   13/112 1   1  
Yes 66 (37%) 26/66 2.18 (1.22–3.87)   1.69 (0.92–3.10)   18/66 2.20 (1.08–4.49)   1.56 (0.76–3.20)  
Targeted therapy in the past 3months     0.66      0.09   
No 148 (83%) 40/148 1     29/148 1    
Yes 30 (17%) 7/30 0.83 (0.37–1.86)     2/30 0.29 (0.07–1.24)    
Immune checkpoint inhibitors in the past 3months     0.39      0.94   
No 159 (89%) 44/159 1     28/159 1    
Yes 19 (11%) 3/19 0.60 (0.19–1.93)     3/19 1.05 (0.32–3.45)    
Hormone therapy in the past 3months (patient with a solid tumor only)     0.85      0.89   
No 140 (90%) 33/140 1     24/140 1    
Yes 16 (10%) 4/16 1.11 (0.39–3.13)     3/16 1.09 (0.33–3.61)    
  1. The hazard ratio corresponds to the effect size of the covariable studied on the risk of clinical worsening or death. Statistical significance was determined by Cox models using the Wald test. Due to the exploratory nature of the analyses, no formal adjustment for multiplicity was done. All tests were two sided and significance was accepted at the 5% level.